The Globalization of Clinical Trials for New Medicines: Where are the Trials Going and Why?
Ernst R. Berndt
Massachusetts Institute of Technology (MIT) - Sloan School of Management; National Bureau of Economic Research (NBER)
Iain M. Cockburn
Boston University School of Management; National Bureau of Economic Research (NBER)
Fabio A. Thiers
Massachusetts Institute of Technology (MIT)
iHEA 2007 6th World Congress: Explorations in Health Economics Paper
We begin by documenting trends in the changing geographical location of clinical trials for new medicines since 2002, away from Western Europe and Canada, and towards Eastern Europe, Latin America and Asia. We then develop a framework for modeling the factors affecting the globalization of clinical trials, particularly into emerging economies. Factors we investigate include country-specific measures of medical infrastructure, costs per patient in the trial, intellectual property protection, size of potential host country market for pharmaceuticals, and measures of e-readiness. We find that factors affecting the globalization process are relative costs per patient, changing intellectual property protection, size of the host country's potential market size, and human capital capabilities.
Keywords: clinical trials, globalization, emerging economies, intellectual property
JEL Classification: F21, I11, C90working papers series
Date posted: June 11, 2007
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo2 in 0.703 seconds